{{distinguish|gliclazide|glyburide}}
{{medref|date=May 2015}}

{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444731264
| IUPAC_name = ''N''-(4-[''N''-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-5-methylpyrazine-2-carboxamide
| image = Glipizide.svg
| image2 = Glipizide ball-and-stick.png
<!--Clinical data-->
| tradename = Glucotrol 
| Drugs.com = {{drugs.com|monograph|glipizide}}
| MedlinePlus = a684060
| pregnancy_AU = C
| pregnancy_US = C
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = POM
| legal_US = Rx only
| legal_status = 
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 100% (regular formulation)<br>90% (extended release)
| protein_bound = 98 to 99%
| metabolism = [[Liver|Hepatic]] [[hydroxylation]]
| elimination_half-life = 2 to 5 hours
| excretion = [[Kidney|Renal]] and fecal
<!--Identifiers-->
| IUPHAR_ligand = 6821
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 29094-61-9
| ATC_prefix = A10
| ATC_suffix = BB07
| PubChem = 3478
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01067
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3359
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = X7WDT95N5C
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00335
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 5384
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1073
<!--Chemical data-->
| C=21 | H=27 | N=5 | O=4 | S=1
| molecular_weight = 445.536 g/mol
| SMILES = O=C(c1ncc(nc1)C)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZJJXGWJIGJFDTL-UHFFFAOYSA-N
}}
'''Glipizide''' is an [[oral administration|oral]] rapid- and short-acting [[anti-diabetic medication]] from the [[sulfonylurea]] class. It is classified as a second-generation sulfonylurea, which means that it undergoes [[enterohepatic circulation]]. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas. 

Originally available in 1984, it is marketed by [[Pfizer]] under the brand name '''Glucotrol''' in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams. Other companies also market glipizide, most commonly extended release tablets of 5 and 10 milligrams.

==Mechanism of action==
Glipizide acts by partially blocking [[potassium]] channels among [[beta cell]]s of pancreatic [[islets of Langerhans]]. By blocking [[potassium]] channels, the cell depolarizes which results in the opening of voltage-gated calcium channels. The resulting calcium influx encourages insulin release from beta cells. {{mcn|date=March 2017}}

==See also==
*[[Glyburide]]
*[[Tolbutamide]]

==References==
{{Reflist}}

== External links ==
* [http://labeling.pfizer.com/ShowLabeling.aspx?id=579 Glucotrol XL Full U.S. Prescribing Information]. Accessed on July 26, 2005.

{{Oral hypoglycemics and insulin analogs}}
{{Ion channel modulators}}

[[Category:Potassium channel blockers]]
[[Category:Sulfonylureas]]
[[Category:Pyrazines]]